Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/24606Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Papayianni, L. | en |
| dc.contributor.author | Katopodis, K. | en |
| dc.contributor.author | Kosmanou, J. | en |
| dc.contributor.author | Banioti, A. | en |
| dc.contributor.author | Katsaraki, A. | en |
| dc.contributor.author | Palatzidou, M. | en |
| dc.contributor.author | Prokopiou, F. | en |
| dc.contributor.author | Betsiou, V. | en |
| dc.contributor.author | Siamopoulos, K. C. | en |
| dc.date.accessioned | 2015-11-24T19:42:13Z | - |
| dc.date.available | 2015-11-24T19:42:13Z | - |
| dc.identifier.issn | 1019-083X | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/24606 | - |
| dc.rights | Default Licence | - |
| dc.subject | Adult | en |
| dc.subject | Aged | en |
| dc.subject | Aluminum Hydroxide/*administration & dosage | en |
| dc.subject | Antacids/*administration & dosage | en |
| dc.subject | Chronic Disease | en |
| dc.subject | Drug Administration Schedule | en |
| dc.subject | Drug Monitoring | en |
| dc.subject | *Feeding Behavior | en |
| dc.subject | Female | en |
| dc.subject | Humans | en |
| dc.subject | Hyperparathyroidism, Secondary/blood/*drug therapy/etiology | en |
| dc.subject | Male | en |
| dc.subject | Middle Aged | en |
| dc.subject | Phosphates/blood | en |
| dc.subject | Renal Dialysis | en |
| dc.subject | Uremia/*complications | en |
| dc.title | The control of hyperphosphataemia in haemodialysis patients | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/9664020 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 1997 | - |
| heal.abstract | Patients with chronic uraemia develop various metabolic abnormalities, the most significant being the low production of vitamin D [1.25(OH)2D3] by the kidneys (1-3), hyperphosphataemia, and hypocalcaemia (4). These abnormalities, occurring usually in combination, are responsible for the pathogenesis of secondary hyperparathyroidism (HPT) (5-11). Prevention and treatment of secondary HPT can be achieved by means of administration of vitamin D and calcium. However, the above treatment is conditional on a low serum phosphorus concentration. | en |
| heal.journalName | EDTNA ERCA J | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
There are no files associated with this item.
This item is licensed under a Creative Commons License
